한글목차

신경근 질환 치료 시장, 2025-2029년

신경근 질환 치료 시장은 2024-2029년에 137억 2,750만 달러, 예측 기간 중 CAGR은 14.6%로 성장할 것으로 예측됩니다. 신경근 질환 치료 시장의 전체적인 분석, 시장 규모·예측, 동향, 성장 촉진요인, 과제, 약 25개의 벤더를 다룬 벤더 분석 등을 게재하고 있습니다.

현재 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공하고 있습니다. 신경근 질환 치료의 신규 승인, 신생아 스크리닝 검사에 대한 요구의 증가, 신경근 질환 치료에 대한 방대한 미충족 요구가 시장을 촉진하고 있습니다.

본 조사에서는 향후 수년간 신경근 질환 치료 시장 성장을 촉진하는 주요 요인의 하나로 신경근 질환 치료에서의 기술 진보를 들고 있습니다. 또한 신경근 질환의 유전적 성질 및 신경근 질환 치료 개발 연구의 증가는 시장의 큰 수요로 연결됩니다.

목차

제1장 개요

• 시장 개요

제2장 Technavio 분석

• 가격·수명주기·고객 구입 바스켓·채택률·구입 기준 분석
• 인풋의 중요성과 차별화의 요인
• 혼란의 요인
• 촉진요인과 과제의 영향

제3장 시장 구도

• 시장 에코시스템
• 시장의 특징
• 밸류체인 분석

제4장 시장 규모

• 시장 정의
• 시장 부문 분석
• 시장 규모 2024년
• 시장 전망 2024-2029년

제5장 시장 규모 실적

• 세계의 신경근 질환 치료 시장 2019-2023년
• 최종사용자별 부문 분석 2019-2023년
• 유형별 부문 분석 2019-2023년
• 지역별 부문 분석 2019-2023년
• 국가별 부문 분석 2019-2023년

제6장 정성 분석

• AI의 영향 : 세계의 신경근 질환 치료 시장

제7장 Five Forces 분석

• Five Forces 요약
• 바이어의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁의 위협
• 시장 현황

제8장 시장 세분화 : 최종사용자별

• 시장 부문
• 비교 : 최종사용자별
• 병원 : 시장 규모와 예측 2024-2029년
• 클리닉 : 시장 규모와 예측 2024-2029년
• 기타 : 시장 규모와 예측 2024-2029년
• 시장 기회 : 최종사용자별

제9장 시장 세분화 : 유형별

• 시장 부문
• 비교 : 유형별
• 생물제제 : 시장 규모와 예측 2024-2029년
• 소분자 : 시장 규모와 예측 2024-2029년
• 시장 기회 : 유형별

제10장 고객 상황

• 고객 상황 개요

제11장 지역별 상황

• 지역별 세분화
• 비교 : 지역별
• 북미 : 시장 규모와 예측 2024-2029년
• 유럽 : 시장 규모와 예측 2024-2029년
• 아시아 : 시장 규모와 예측 2024-2029년
• 기타 : 시장 규모와 예측 2024-2029년
• 미국 : 시장 규모와 예측 2024-2029년
• 독일 : 시장 규모와 예측 2024-2029년
• 영국 : 시장 규모와 예측 2024-2029년
• 중국 : 시장 규모와 예측 2024-2029년
• 캐나다 : 시장 규모와 예측 2024-2029년
• 프랑스 : 시장 규모와 예측 2024-2029년
• 일본 : 시장 규모와 예측 2024-2029년
• 인도 : 시장 규모와 예측 2024-2029년
• 이탈리아 : 시장 규모와 예측 2024-2029년
• 한국 : 시장 규모와 예측 2024-2029년
• 지역 상황에 의한 시장 기회

제12장 촉진요인·과제·기회·억제요인

• 시장 성장 촉진요인
• 시장이 해결해야 할 과제
• 촉진요인과 과제의 영향
• 시장 기회·억제요인

제13장 경쟁 구도

• 개요
• 경쟁 구도
• 혼란 상황
• 산업 리스크

제14장 경쟁 분석

• 기업 개요
• 기업 순위 지수
• 기업의 시장 포지셔닝
• AbbVie Inc.
• Aquestive Therapeutics Inc
• argenx SE
• AstraZeneca Plc
• Biogen Inc.
• F. Hoffmann La Roche Ltd.
• Grifols SA
• Merck and Co. Inc.
• Nippon Shinyaku Co. Ltd.
• Novartis AG
• Pfizer Inc.
• Roivant Sciences Ltd.
• Santhera Pharmaceuticals Holding AG
• Sarepta Therapeutics Inc.
• Takeda Pharmaceutical Co. Ltd.

제15장 부록

영문목차

Neuromuscular Disease Therapeutics Market 2025-2029

The neuromuscular disease therapeutics market is forecasted to grow by USD 13727.5 mn during 2024-2029, accelerating at a CAGR of 14.6% during the forecast period. The report on the neuromuscular disease therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by novel approvals for neuromuscular disease therapeutics, increasing need for newborn screening tests, and huge unmet need for neuromuscular disease therapeutics.

Technavio's neuromuscular disease therapeutics market is segmented as below:

By End-user

• Hospitals
• Clinics
• Others

By Type

• Biologics
• Small molecules

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the technological advances in neuromuscular disease therapy as one of the prime reasons driving the neuromuscular disease therapeutics market growth during the next few years. Also, inherited nature of neuromuscular diseases and increasing research on developing therapeutics for neuromuscular disease will lead to sizable demand in the market.

The report on the neuromuscular disease therapeutics market covers the following areas:

• Neuromuscular Disease Therapeutics Market sizing
• Neuromuscular Disease Therapeutics Market forecast
• Neuromuscular Disease Therapeutics Market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neuromuscular disease therapeutics market vendors that include AbbVie Inc., Aquestive Therapeutics Inc, argenx SE, AstraZeneca Plc, Biogen Inc., CuraVac, F. Hoffmann La Roche Ltd., Grifols SA, Merck and Co. Inc., Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., Roivant Sciences Ltd., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd.. Also, the neuromuscular disease therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market By Geographical Landscape
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
  • Overview on criticality of inputs and factors of differentiation
• 2.3 Factors of disruption
  • Overview on factors of disruption
• 2.4 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029

3 Market Landscape

• 3.1 Market ecosystem
  • Parent Market
  • Data Table on - Parent Market
• 3.2 Market characteristics
  • Market characteristics analysis
• 3.3 Value chain analysis
  • Value chain analysis

4 Market Sizing

• 4.1 Market definition
  • Offerings of companies included in the market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2024
• 4.4 Market outlook: Forecast for 2024-2029
  • Chart on Global - Market size and forecast 2024-2029 ($ million)
  • Data Table on Global - Market size and forecast 2024-2029 ($ million)
  • Chart on Global Market: Year-over-year growth 2024-2029 (%)
  • Data Table on Global Market: Year-over-year growth 2024-2029 (%)

5 Historic Market Size

• 5.1 Global Neuromuscular Disease Therapeutics Market 2019 - 2023
  • Historic Market Size - Data Table on Global Neuromuscular Disease Therapeutics Market 2019 - 2023 ($ million)
• 5.2 End-user segment analysis 2019 - 2023
  • Historic Market Size - End-user Segment 2019 - 2023 ($ million)
• 5.3 Type segment analysis 2019 - 2023
  • Historic Market Size - Type Segment 2019 - 2023 ($ million)
• 5.4 Geography segment analysis 2019 - 2023
  • Historic Market Size - Geography Segment 2019 - 2023 ($ million)
• 5.5 Country segment analysis 2019 - 2023
  • Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Neuromuscular Disease Therapeutics Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2024 and 2029
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2024 and 2029
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2024 and 2029
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2024 and 2029
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2024 and 2029
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2024 and 2029
• 7.7 Market condition
  • Chart on Market condition - Five forces 2024 and 2029

8 Market Segmentation by End-user

• 8.1 Market segments
  • Chart on End-user - Market share 2024-2029 (%)
  • Data Table on End-user - Market share 2024-2029 (%)
• 8.2 Comparison by End-user
  • Chart on Comparison by End-user
  • Data Table on Comparison by End-user
• 8.3 Hospitals - Market size and forecast 2024-2029
  • Chart on Hospitals - Market size and forecast 2024-2029 ($ million)
  • Data Table on Hospitals - Market size and forecast 2024-2029 ($ million)
  • Chart on Hospitals - Year-over-year growth 2024-2029 (%)
  • Data Table on Hospitals - Year-over-year growth 2024-2029 (%)
• 8.4 Clinics - Market size and forecast 2024-2029
  • Chart on Clinics - Market size and forecast 2024-2029 ($ million)
  • Data Table on Clinics - Market size and forecast 2024-2029 ($ million)
  • Chart on Clinics - Year-over-year growth 2024-2029 (%)
  • Data Table on Clinics - Year-over-year growth 2024-2029 (%)
• 8.5 Others - Market size and forecast 2024-2029
  • Chart on Others - Market size and forecast 2024-2029 ($ million)
  • Data Table on Others - Market size and forecast 2024-2029 ($ million)
  • Chart on Others - Year-over-year growth 2024-2029 (%)
  • Data Table on Others - Year-over-year growth 2024-2029 (%)
• 8.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)
  • Data Table on Market opportunity by End-user ($ million)

9 Market Segmentation by Type

• 9.1 Market segments
  • Chart on Type - Market share 2024-2029 (%)
  • Data Table on Type - Market share 2024-2029 (%)
• 9.2 Comparison by Type
  • Chart on Comparison by Type
  • Data Table on Comparison by Type
• 9.3 Biologics - Market size and forecast 2024-2029
  • Chart on Biologics - Market size and forecast 2024-2029 ($ million)
  • Data Table on Biologics - Market size and forecast 2024-2029 ($ million)
  • Chart on Biologics - Year-over-year growth 2024-2029 (%)
  • Data Table on Biologics - Year-over-year growth 2024-2029 (%)
• 9.4 Small molecules - Market size and forecast 2024-2029
  • Chart on Small molecules - Market size and forecast 2024-2029 ($ million)
  • Data Table on Small molecules - Market size and forecast 2024-2029 ($ million)
  • Chart on Small molecules - Year-over-year growth 2024-2029 (%)
  • Data Table on Small molecules - Year-over-year growth 2024-2029 (%)
• 9.5 Market opportunity by Type
  • Market opportunity by Type ($ million)
  • Data Table on Market opportunity by Type ($ million)

10 Customer Landscape

• 10.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

11 Geographic Landscape

• 11.1 Geographic segmentation
  • Chart on Market share By Geographical Landscape 2024-2029 (%)
  • Data Table on Market share By Geographical Landscape 2024-2029 (%)
• 11.2 Geographic comparison
  • Chart on Geographic comparison
  • Data Table on Geographic comparison
• 11.3 North America - Market size and forecast 2024-2029
  • Chart on North America - Market size and forecast 2024-2029 ($ million)
  • Data Table on North America - Market size and forecast 2024-2029 ($ million)
  • Chart on North America - Year-over-year growth 2024-2029 (%)
  • Data Table on North America - Year-over-year growth 2024-2029 (%)
• 11.4 Europe - Market size and forecast 2024-2029
  • Chart on Europe - Market size and forecast 2024-2029 ($ million)
  • Data Table on Europe - Market size and forecast 2024-2029 ($ million)
  • Chart on Europe - Year-over-year growth 2024-2029 (%)
  • Data Table on Europe - Year-over-year growth 2024-2029 (%)
• 11.5 Asia - Market size and forecast 2024-2029
  • Chart on Asia - Market size and forecast 2024-2029 ($ million)
  • Data Table on Asia - Market size and forecast 2024-2029 ($ million)
  • Chart on Asia - Year-over-year growth 2024-2029 (%)
  • Data Table on Asia - Year-over-year growth 2024-2029 (%)
• 11.6 Rest of World (ROW) - Market size and forecast 2024-2029
  • Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
  • Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
  • Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
  • Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
• 11.7 US - Market size and forecast 2024-2029
  • Chart on US - Market size and forecast 2024-2029 ($ million)
  • Data Table on US - Market size and forecast 2024-2029 ($ million)
  • Chart on US - Year-over-year growth 2024-2029 (%)
  • Data Table on US - Year-over-year growth 2024-2029 (%)
• 11.8 Germany - Market size and forecast 2024-2029
  • Chart on Germany - Market size and forecast 2024-2029 ($ million)
  • Data Table on Germany - Market size and forecast 2024-2029 ($ million)
  • Chart on Germany - Year-over-year growth 2024-2029 (%)
  • Data Table on Germany - Year-over-year growth 2024-2029 (%)
• 11.9 UK - Market size and forecast 2024-2029
  • Chart on UK - Market size and forecast 2024-2029 ($ million)
  • Data Table on UK - Market size and forecast 2024-2029 ($ million)
  • Chart on UK - Year-over-year growth 2024-2029 (%)
  • Data Table on UK - Year-over-year growth 2024-2029 (%)
• 11.10 China - Market size and forecast 2024-2029
  • Chart on China - Market size and forecast 2024-2029 ($ million)
  • Data Table on China - Market size and forecast 2024-2029 ($ million)
  • Chart on China - Year-over-year growth 2024-2029 (%)
  • Data Table on China - Year-over-year growth 2024-2029 (%)
• 11.11 Canada - Market size and forecast 2024-2029
  • Chart on Canada - Market size and forecast 2024-2029 ($ million)
  • Data Table on Canada - Market size and forecast 2024-2029 ($ million)
  • Chart on Canada - Year-over-year growth 2024-2029 (%)
  • Data Table on Canada - Year-over-year growth 2024-2029 (%)
• 11.12 France - Market size and forecast 2024-2029
  • Chart on France - Market size and forecast 2024-2029 ($ million)
  • Data Table on France - Market size and forecast 2024-2029 ($ million)
  • Chart on France - Year-over-year growth 2024-2029 (%)
  • Data Table on France - Year-over-year growth 2024-2029 (%)
• 11.13 Japan - Market size and forecast 2024-2029
  • Chart on Japan - Market size and forecast 2024-2029 ($ million)
  • Data Table on Japan - Market size and forecast 2024-2029 ($ million)
  • Chart on Japan - Year-over-year growth 2024-2029 (%)
  • Data Table on Japan - Year-over-year growth 2024-2029 (%)
• 11.14 India - Market size and forecast 2024-2029
  • Chart on India - Market size and forecast 2024-2029 ($ million)
  • Data Table on India - Market size and forecast 2024-2029 ($ million)
  • Chart on India - Year-over-year growth 2024-2029 (%)
  • Data Table on India - Year-over-year growth 2024-2029 (%)
• 11.15 Italy - Market size and forecast 2024-2029
  • Chart on Italy - Market size and forecast 2024-2029 ($ million)
  • Data Table on Italy - Market size and forecast 2024-2029 ($ million)
  • Chart on Italy - Year-over-year growth 2024-2029 (%)
  • Data Table on Italy - Year-over-year growth 2024-2029 (%)
• 11.16 South Korea - Market size and forecast 2024-2029
  • Chart on South Korea - Market size and forecast 2024-2029 ($ million)
  • Data Table on South Korea - Market size and forecast 2024-2029 ($ million)
  • Chart on South Korea - Year-over-year growth 2024-2029 (%)
  • Data Table on South Korea - Year-over-year growth 2024-2029 (%)
• 11.17 Market opportunity By Geographical Landscape
  • Market opportunity By Geographical Landscape ($ million)
  • Data Tables on Market opportunity By Geographical Landscape ($ million)

12 Drivers, Challenges, and Opportunity/Restraints

• 12.1 Market drivers
• 12.2 Market challenges
• 12.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029
• 12.4 Market opportunities/restraints

13 Competitive Landscape

• 13.1 Overview
• 13.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 13.3 Landscape disruption
  • Overview on factors of disruption
• 13.4 Industry risks
  • Impact of key risks on business

14 Competitive Analysis

• 14.1 Companies profiled
  • Companies covered
• 14.2 Company ranking index
  • Company ranking index
• 14.3 Market positioning of companies
  • Matrix on companies position and classification
• 14.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Product / Service
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • SWOT
• 14.5 Aquestive Therapeutics Inc
  • Aquestive Therapeutics Inc - Overview
  • Aquestive Therapeutics Inc - Key offerings
  • SWOT
• 14.6 argenx SE
  • argenx SE - Overview
  • argenx SE - Product / Service
  • argenx SE - Key offerings
  • SWOT
• 14.7 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • SWOT
• 14.8 Biogen Inc.
  • Biogen Inc. - Overview
  • Biogen Inc. - Product / Service
  • Biogen Inc. - Key news
  • Biogen Inc. - Key offerings
  • SWOT
• 14.9 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 14.10 Grifols SA
  • Grifols SA - Overview
  • Grifols SA - Business segments
  • Grifols SA - Key news
  • Grifols SA - Key offerings
  • Grifols SA - Segment focus
  • SWOT
• 14.11 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT
• 14.12 Nippon Shinyaku Co. Ltd.
  • Nippon Shinyaku Co. Ltd. - Overview
  • Nippon Shinyaku Co. Ltd. - Business segments
  • Nippon Shinyaku Co. Ltd. - Key offerings
  • Nippon Shinyaku Co. Ltd. - Segment focus
  • SWOT
• 14.13 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 14.14 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Product / Service
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • SWOT
• 14.15 Roivant Sciences Ltd.
  • Roivant Sciences Ltd. - Overview
  • Roivant Sciences Ltd. - Product / Service
  • Roivant Sciences Ltd. - Key offerings
  • SWOT
• 14.16 Santhera Pharmaceuticals Holding AG
  • Santhera Pharmaceuticals Holding AG - Overview
  • Santhera Pharmaceuticals Holding AG - Product / Service
  • Santhera Pharmaceuticals Holding AG - Key offerings
  • SWOT
• 14.17 Sarepta Therapeutics Inc.
  • Sarepta Therapeutics Inc. - Overview
  • Sarepta Therapeutics Inc. - Product / Service
  • Sarepta Therapeutics Inc. - Key offerings
  • SWOT
• 14.18 Takeda Pharmaceutical Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd. - Overview
  • Takeda Pharmaceutical Co. Ltd. - Product / Service
  • Takeda Pharmaceutical Co. Ltd. - Key news
  • Takeda Pharmaceutical Co. Ltd. - Key offerings
  • SWOT

15 Appendix

• 15.1 Scope of the report
• 15.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 15.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 15.4 Research methodology
  • Research methodology
• 15.5 Data procurement
  • Information sources
• 15.6 Data validation
  • Data validation
• 15.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 15.8 Data synthesis
  • Data synthesis
• 15.9 360 degree market analysis
  • 360 degree market analysis
• 15.10 List of abbreviations
  • List of abbreviations